Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls - Takeaway - MDSpire

Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls

Share

  • 1

    CTNNA1 germline variants are linked to hereditary diffuse gastric cancer (HDGC), with truncating variants posing a moderate risk compared to CDH1 variants.

  • 2

    The study identifies the pathophysiological mechanism for CTNNA1-truncating variants, establishing them as key contributors to HDGC.

  • 3

    Clinical criteria for CTNNA1 genetic testing were proposed, enhancing the identification of individuals at risk for HDGC.

  • 4

    CTNNA1-truncating variants lead to increased likelihood of developing gastric cancer compared to wild-type individuals.

  • 5

    This research provides the largest dataset on CTNNA1-associated diseases, aiding in clinical management and variant classification.

Original Source(s)

Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls

  • by Silvana Lobo, Alexandre Dias, Ana Maria Pedro, Marta Ferreira, André Pinto-Oliveira, Celina São José, Jennifer Herrera-Mullar, Nádia Pinto, Chrystelle Colas, Robert Hüneburg, Jacob Nattermann, Lise Boussemart, Liselotte P van Hest, Leticia Moreira, Carolyn Horton, Dana Farengo Clark, Sigrid Tinschert, Lisa Golmard, Isabel Spier, Adriá López-Fernández, Daniela Oliveira, Magali SVRCEK, Pierre Bourgoin, Florence Coulet, Hélène Delhomelle, Jeremy Davis, Birthe Zäncker, Conxi Lazaro, Joana Guerra, Maria L Almeida, Sergio Carrera, Ana Patiño, Paul Gundlach, Monika Laszkowska, Vivian E Strong, Manuel R Teixeira, Intan Schrader, Verena Steinke-Lange, Irene Gullo, Sérgio Sousa, Manuela Batista, Stefan Aretz, Judith Balmaña, Melyssa Aronson, Augusto Perazzolo Antoniazzi, Edenir I Palmero, Paul Mansfield, Lizet E van der Kolk, Annemieke Cats, Jolanda M van Dieren, Sergi Castellví-Bel, Bryson Katona, Rachid Karam, Paulo S Pereira, Patrick R Benusiglio, Carla Oliveira

  • May 1, 2026

Related Content

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...

Trends and Challenges in Nitrosamine Testing Part Four The Regulatory Landscape

Following part two, which explored the analytical challenges involved in nitrosamine testing, our experts return to offer their top tips for building a method from scratch

  • April 17, 2026

  • 6 min
Is Standard of Care Optimal for the Individual Patient?

I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded ...